- Home
- IDYA vs SPH Comparison
IDYA vs SPH Comparison
Compare IDYA & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SPH
- Stock Information
- Founded
- IDYA 2015
- SPH 1945
- Country
- IDYA United States
- SPH United States
- Employees
- IDYA N/A
- SPH N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SPH Other Specialty Stores
- Sector
- IDYA Health Care
- SPH Consumer Discretionary
- Exchange
- IDYA Nasdaq
- SPH Nasdaq
- Market Cap
- IDYA 1.5B
- SPH 1.3B
- IPO Year
- IDYA 2019
- SPH 1996
- Fundamental
- Price
- IDYA $21.22
- SPH $19.00
- Analyst Decision
- IDYA Strong Buy
- SPH Buy
- Analyst Count
- IDYA 12
- SPH 2
- Target Price
- IDYA $54.27
- SPH $21.00
- AVG Volume (30 Days)
- IDYA 1.5M
- SPH 146.0K
- Earning Date
- IDYA 05-06-2025
- SPH 05-08-2025
- Dividend Yield
- IDYA N/A
- SPH 6.83%
- EPS Growth
- IDYA N/A
- SPH N/A
- EPS
- IDYA N/A
- SPH 1.46
- Revenue
- IDYA $7,000,000.00
- SPH $1,424,243,000.00
- Revenue This Year
- IDYA $68.39
- SPH $7.97
- Revenue Next Year
- IDYA $324.54
- SPH $1.74
- P/E Ratio
- IDYA N/A
- SPH $12.91
- Revenue Growth
- IDYA N/A
- SPH 4.02
- 52 Week Low
- IDYA $13.45
- SPH $15.20
- 52 Week High
- IDYA $44.42
- SPH $22.24
- Technical
- Relative Strength Index (RSI)
- IDYA 65.40
- SPH 42.15
- Support Level
- IDYA $19.26
- SPH $18.76
- Resistance Level
- IDYA $20.46
- SPH $19.40
- Average True Range (ATR)
- IDYA 1.01
- SPH 0.41
- MACD
- IDYA 0.24
- SPH 0.00
- Stochastic Oscillator
- IDYA 99.55
- SPH 25.00
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.